TNF and chronic obstructive pulmonary disease: However, a multicenter, randomized controlled trial involving patients with moderate-to-severe COPD showed that infliximab did not significantly improve lung function or quality of life, nor did it reduce exacerbation rates compared with a placebo, despite the proposed role of TNF-α in COPD pathogenesis [31].